Labcorp Holdings Ord
LH
Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them
Managers holding
2
In their latest 13F (Q3 2026)
See who
Value held
$32.2m
Combined value at quarter end
Last quarter
0 bought
1 sold or trimmed
Fund portfolios
1
Funds holding it
See which
Price at Q2 ’26 end
$280.00
+4.9% in the quarter
Share price change by quarter
+9.8%Q3 ’24
+2.6%Q4 ’24
+1.5%Q1 ’25
+12.8%Q2 ’25
+9.4%Q3 ’25
-12.6%Q4 ’25
+6.3%Q1 ’26
+4.9%Q2 ’26
Managers holding it, by quarter
0Q4 ’23
0Q1 ’24
2Q2 ’24
2Q3 ’24
2Q4 ’24
2Q1 ’25
2Q2 ’25
2Q3 ’25
2Q4 ’25
2Q1 ’26
2Q2 ’26
0Q3 ’26
Who holds it
| Weitz Investment Management | 1.9%$27.7m | Unchanged |
| Jensen Investment Management | 0.1%$4.5m | Trimmed -13% |
About the company
- Sector
- Health care · Services-Medical Laboratories
- Financial year ends
- 31 December
- Shares outstanding
- 81m at 4 Aug 2026
- SEC filings
- Annual reports and other filings on EDGAR
Revenue and profit
$5.8bn2013
$6.0bn2014
$14bn2020
$13bn2021
$12bn2022
$12bn2023
$13bn2024
$14bn2025
| Year | Revenue | Net income |
|---|---|---|
| 2025 | $14bn | $877m |
| 2024 | $13bn | $746m |
| 2023 | $12bn | $418m |
| 2022 | $12bn | $1.3bn |
| 2021 | $13bn | $2.4bn |
| 2020 | $14bn | $1.6bn |
| 2014 | $6.0bn | $511m |
| 2013 | $5.8bn | $574m |
In fund portfolios
| Weitz Partners Value FundWeitz Investment Management | 4.6% |